30Mar
30Mar
Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder. “There is no cure for MPS I, and there is a significant unmet need for therapies that...
27Mar
GelMEDIX, Catalent Partner to Advance iPSC-Derived Cell Therapies
GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent Inc., a global contract development and manufacturing organization (CDMO), have partnered to utilize Catalent’s GMP-induced pluripotent stem cells (iPSC) and cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases. Read More>>
02Mar
Akston Chooses Louisiana for Major Life Sciences Manufacturing Expansion
SHREVEPORT, La. — Akston, a biotechnology company focused on animal health, has opened a new manufacturing facility as part of a $7 million investment in Caddo Parish to expand its U.S. manufacturing capabilities and strengthen Louisiana’s life sciences sector. Read More>>
17Feb
GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership
— Proceeds to support advancement of lead cell therapy program for Geographic Atrophy and next-generation hydrogel regenerative therapy platform — — Partnership with global pharmaceutical company will leverage GelMEDIX regenerative medicine technology to develop stem cell-derived cell therapies — CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor...
26Jan
“When sport teams tell you what tech they use, people stand up and take notice”: Wasabi tells us how it is helping Liverpool FC score big on content for fans everywhere
With sports teams looking to provide a fast and rich experience for fans across the world, having access to their content is a vital need - but with games, training sessions and even commercial appearances on the go round the clock, getting hold of the right content at the right time can be tricky. One of the most iconic names in world football, Liverpool FC has been working with Wasabi to transform its cloud...
26Nov
Akston Initiates Clinical Trial of Once-Weekly GLP-1 Weight-Management Therapy for Cats
BEVERLY, Mass., Nov. 25, 2025 /PRNewswire/ -- Akston, the Biotech Built for Pets, announced today the start of a clinical study at Cornell University College of Veterinary Medicine to evaluate its once-weekly GLP-1 weight-management therapy for cats. The trial will assess the therapy over a roughly three-month period in client-owned domestic cats affected by excess weight. Excess weight is one of the most common health issues in cats today. According to the Association for Pet Obesity Prevention (APOP)1, 61% of U.S. cats...
19Nov
Wasabi Introduces High-Performance Class and Expands into Silicon Valley to Take on AI’s Rising Data Storage Costs
BOSTON--(BUSINESS WIRE)--Wasabi Technologies, the Hot Cloud Storage company, expanded further into artificial intelligence with the unveiling of Wasabi Fire, a high-performance storage class that supports AI workloads, available beginning in early 2026. Wasabi has also opened a new storage region in San Jose, Calif., as part of its relationship with IBM Cloud. The milestones reinforce Wasabi’s push to expand its role in AI infrastructure as demand for scalable, high-performance and cost-efficient cloud...
07Nov
RevBio® Receives First FDA Approval for a “Bone Glue” to Treat Extremity Fractures in a Clinical Trial
LOWELL, Mass.--(BUSINESS WIRE)--RevBio® announced today that TETRANITE, the company’s first of its kind regenerative “bone glue” has been approved for a 20-patient pilot study to measure the biomaterial’s safety and efficacy to treat complex, multi-fragmented wrist fractures including those that involve articular surfaces. Read More>>
31Oct